Compile Data Set for Download or QSAR
maximum 50k data
Found 50 Enz. Inhib. hit(s) with all data for entry = 9745
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251923(BDBM272562 | US10683295, Compound 25 | US10941151,...)
Affinity DataKi:  3nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081196(CHEMBL3422015 | US10065961, Compound 13 | US106832...)
Affinity DataKi:  3nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251909(US10065961, Compound 7 | US10683295, Compound 7 | ...)
Affinity DataKi:  4nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251907(US10065961, Compound 5 | US10683295, Compound 5 | ...)
Affinity DataKi:  5nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081399(CHEMBL3422016 | US10065961, Compound 19 | US106832...)
Affinity DataKi:  6nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251910(US10065961, Compound 8 | US10683295, Compound 8 | ...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081293(CHEMBL3422007 | US10065961, Compound 30 | US106832...)
Affinity DataKi:  10nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081293(CHEMBL3422007 | US10065961, Compound 30 | US106832...)
Affinity DataKi:  10nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251916(US10065961, Compound 15 | US10683295, Compound 15 ...)
Affinity DataKi:  11nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251908(US10065961, Compound 6 | US10683295, Compound 6 | ...)
Affinity DataKi:  11nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251920(US10065961, Compound 20 | US10683295, Compound 20 ...)
Affinity DataKi:  12nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081195(CHEMBL3422010 | US10065961, Compound 1 | US1068329...)
Affinity DataKi:  16nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081195(CHEMBL3422010 | US10065961, Compound 1 | US1068329...)
Affinity DataKi:  16nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251911(US10065961, Compound 9 | US10683295, Compound 9 | ...)
Affinity DataKi:  19nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM485815((3-(2-isopropylthiazol-4-yl)- 5,6-dihydro- [1,2,4]...)
Affinity DataKi:  20nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251922(US10065961, Compound 22 | US10683295, Compound 22 ...)
Affinity DataKi:  21nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251928(US10065961, Compound 31 | US10683295, Compound 31 ...)
Affinity DataKi:  22nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251928(US10065961, Compound 31 | US10683295, Compound 31 ...)
Affinity DataKi:  22nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251927(US10065961, Compound 29 | US10683295, Compound 29 ...)
Affinity DataKi:  23nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251905(US10065961, Compound 2 | US10683295, Compound 2 | ...)
Affinity DataKi:  26nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081197(CHEMBL3422017 | US10065961, Compound 23 | US106832...)
Affinity DataKi:  29nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081197(CHEMBL3422017 | US10065961, Compound 23 | US106832...)
Affinity DataKi:  29nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251917(US10065961, Compound 16 | US10941151, Compound 16 ...)
Affinity DataKi:  32nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251912(US10065961, Compound 10 | US10683295, Compound 10 ...)
Affinity DataKi:  36nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251921(US10065961, Compound 21 | US10683295, Compound 21 ...)
Affinity DataKi:  38nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251915(US10065961, Compound 14 | US10683295, Compound 14 ...)
Affinity DataKi:  42nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi:  44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi:  44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM272564((R)-4-methyl-2-(8-methyl- 5,6,7,8-tetrahydro- [1,2...)
Affinity DataKi:  51nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251906(US10065961, Compound 4 | US10683295, Compound 4 | ...)
Affinity DataKi:  56nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251926(US10065961, Compound 28 | US10683295, Compound 28 ...)
Affinity DataKi:  68nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251914(US10065961, Compound 12 | US10683295, Compound 12 ...)
Affinity DataKi:  70nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081363(CHEMBL3422012 | US10065961, Compound 3 | US1068329...)
Affinity DataKi:  83nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081363(CHEMBL3422012 | US10065961, Compound 3 | US1068329...)
Affinity DataKi:  83nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081293(CHEMBL3422007 | US10065961, Compound 30 | US106832...)
Affinity DataKi:  5.93E+3nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  6.06E+3nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251918(US10065961, Compound 17 | US10683295, Compound 17 ...)
Affinity DataKi:  9.95E+3nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081197(CHEMBL3422017 | US10065961, Compound 23 | US106832...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081197(CHEMBL3422017 | US10065961, Compound 23 | US106832...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081363(CHEMBL3422012 | US10065961, Compound 3 | US1068329...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081363(CHEMBL3422012 | US10065961, Compound 3 | US1068329...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251928(US10065961, Compound 31 | US10683295, Compound 31 ...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251928(US10065961, Compound 31 | US10683295, Compound 31 ...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081195(CHEMBL3422010 | US10065961, Compound 1 | US1068329...)
Affinity DataKi:  1.27E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081195(CHEMBL3422010 | US10065961, Compound 1 | US1068329...)
Affinity DataKi:  1.40E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50081293(CHEMBL3422007 | US10065961, Compound 30 | US106832...)
Affinity DataKi:  1.72E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
In DepthDetails US Patent